What’s next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination

Research output: Contribution to journalReview articlepeer-review

6 Citations (Scopus)

Abstract

The process of tumorigenesis leaves a series of indelible genetic changes in tumor cells, that when expressed, have the potential to be tumor-specific immune targets. Neoantigen vaccines that capitalize on this potential immunogenicity have shown efficacy in preclinical models and have now entered clinical trials. Here we discuss the status of personalized neoantigen vaccines and the current major challenges to this nascent field. In particular, we focus on the types of antigens that can be targeted by vaccination and on the role that preexisting immunosuppression, and in particular T-cell exhaustion, will play in the development of effective cancer vaccines.

Original languageEnglish
Article number2038403
JournalOncoImmunology
Volume11
Issue number1
DOIs
Publication statusPublished - 13 Feb 2022

Fingerprint

Dive into the research topics of 'What’s next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination'. Together they form a unique fingerprint.

Cite this